Results 71 to 80 of about 1,770,471 (326)

Essential plasticity and redundancy of metabolism unveiled by synthetic lethality analysis

, 2014
We unravel how functional plasticity and redundancy are essential mechanisms underlying the ability to survive of metabolic networks. We perform an exhaustive computational screening of synthetic lethal reaction pairs in Escherichia coli in a minimal ...
Güell, Oriol, Sagués, Francesc, Serrano, M. Ángeles   +2 more
core   +3 more sources

Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells [PDF]

, 2015
This research was originally published in Journal of Biological Chemistry. Olesya Chayka, Cosimo Walter D’Acunto, Odette Middleton, Maryam Arab, and Arturo Sala.
Arab, M, Chayka, O, D'Acunto, CW, Middleton, O, Sala, A   +4 more
core   +1 more source

Evolving DNA repair synthetic lethality targets in cancer

Bioscience Reports, 2022
DNA damage signaling response and repair (DDR) is a critical defense mechanism against genomic instability. Impaired DNA repair capacity is an important risk factor for cancer development.
Sanat Kulkarni, Juliette Brownlie, J. Jeyapalan, N. Mongan, E. Rakha, S. Madhusudan   +5 more
semanticscholar   +1 more source

Synthetic Lethal Vulnerabilities of Cancer

Annual Review of Pharmacology and Toxicology, 2015
The great majority of targeted anticancer drugs inhibit mutated oncogenes that display increased activity. Yet many tumors do not contain such actionable aberrations, such as those harboring loss-of-function mutations. The notion of targeting synthetic lethal vulnerabilities in cancer cells has provided an alternative approach to exploiting more of ...
Ferran Fece de la Cruz, Bianca V. Gapp, Sebastian M.B. Nijman   +2 more
openaire   +3 more sources

Application and research progress of synthetic lethality in the development of anticancer therapeutic drugs

Frontiers in Oncology
With the tremendous success of the PARP inhibitor olaparib in clinical practice, synthetic lethality has become an important field for the discovery and development of anticancer drugs.
Xiaoliang Gong, Chunxi Liu, Haoyang Tang, Song Wu, Qingyun Yang   +4 more
doaj   +1 more source

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells [PDF]

, 2014
Background Although MYC is an attractive therapeutic target for breast cancer treatment, it has proven challenging to inhibit MYC directly, and clinically effective pharmaceutical agents targeting MYC are not yet available. An alternative approach is to
Kang, Jian, Musgrove, Elizabeth A., Sergio, C. Marcelo, Sutherland, Robert L.   +3 more
core   +2 more sources

Rapid Inhibitor Discovery by Exploiting Synthetic Lethality

Journal of the American Chemical Society, 2022
Synthetic lethality occurs when inactivation of two genes is lethal but inactivation of either single gene is not. This phenomenon provides an opportunity for efficient compound discovery.
Jacob D Muscato, Heidi G. Morris, Aaron Mychack, Mithila Rajagopal, V. Baidin, Anthony R. Hesser, Wonsik Lee, Kemal Inecik, L. J. Wilson, C. Kraml, Timothy C. Meredith, S. Walker   +11 more
semanticscholar   +1 more source

Targeting synthetic lethal paralogs in cancer

Trends in Cancer, 2023
Synthetic lethal interactions, where mutation of one gene renders cells sensitive to inhibition of another gene, can be exploited for the development of targeted therapeutics in cancer. Pairs of duplicate genes (paralogs) often share common functionality and hence are a potentially rich source of synthetic lethal interactions.
Colm J. Ryan, Ishan Mehta, Narod Kebabci, David J. Adams   +3 more
openaire   +2 more sources

Drugging the Cancers Addicted to DNA Repair [PDF]

, 2017
Defects in DNA repair can result in oncogenic genomic instability. Cancers occurring from DNA repair defects were once thought to be limited to rare inherited mutations (such as BRCA1 or 2).
Hromas, Robert, Jones, Dennie, Lee, Suk-Hee, Nickoloff, Jac A., Williamson, Elizabeth A.   +4 more
core   +1 more source

BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality

Journal of Clinical Investigation
Mutations in the tumor-suppressor genes BRCA1 and BRCA2 resulting in BRCA1/2 deficiency are frequently identified in breast, ovarian, prostate, pancreatic, and other cancers. Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectively kill BRCA1/2-
Xin Li, Lee Zou
semanticscholar   +1 more source